COVID-19 Therapies

Refer Patients to Owensboro Health Regional Hospital

The following referral forms are to be used by medical professionals. Patients who are interested in receiving any of the following therapies should ask their current provider for a referral.

Monoclonal Antibody Treatment 

There are currently no Monoclonal Antibody Treatment therapies approved by the FDA to treat the current variant of COVID-19. As therapies become approved, this page will be updated with pertinent information.

Questions?

Please call the OHRH Inpatient Pharmacy at 270-417-6700.

Paxlovid (Oral COVID-19 Therapy)

Nirmatrelivr/ritonavir (Paxlovid) has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid is not authorized for use as a pre-exposure or post-exposure prophylaxis for prevention for COVID-19.

Paxlovid should be initiated as soon as possible after a diagnosis of COVID-19 and within 5 days of symptom onset.  Therapy is twice-daily dosing for 5 days. Renal adjustments are necessary depending on the level of renal function.

INVENTORY STATUS: Limited Supply Available 

To ensure you have the most up-to-date information and Paxlovid Order Form, please visit the link below each day you plan to order Paxlovid.

Download the Paxlovid Referral Form

Questions?

Please call the OHRH Outpatient Pharmacy at 270-417-6701.

Evusheld Monoclonal Antibody Treatment

Tixagevimab and cilgavimab (Evusheld) are authorized for patients not currently infected with COVID-19 and who have not been recently exposed. Evusheld is also to be reserved for patients who are moderate to severely immunocompromised who cannot mount an appropriate response to COVID-19 or who cannot be vaccinated due to a history of severe reactions to the vaccine components. This is NOT to be treated as an alternative to vaccination.

 Evusheld is being restricted to the following indications:

  • Active treatment for solid tumor or hematologic malignancy
  •  Receipt of solid-organ transplant and taking immunosuppressive therapy 
  • Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy) 
  • Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome) 
  • Advanced or untreated HIV infection (people with HIV and CD4 cell counts < 200/mm3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) 
  • Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents)

As more supply becomes available, these indications may expand. This website will have the most up-to-date indications and referral form. 

INVENTORY STATUS: Supply Available

Download the Evusheld Monoclonal Antibody Referral Form

Questions?

Please call the OHRH Inpatient Pharmacy at 270-417-6700.